Figure 2. Tumor-associated endothelial cell FAK and pFAK^Y397 expression in human epithelial ovarian cancer. (A) Representative tumor-associated endothelial cell FAK (FAK-endo) immunohistochemical staining in advanced stage, high grade serous ovarian cancer specimens. Negative FAK-endo expression and FAK-endo overexpression are represented in the left and right panels, respectively. (B) Representative tumor-associated endothelial cell pFAK^Y397 (pFAK-endo) immunohistochemical staining in advanced stage, high grade serous ovarian cancer specimens. Negative pFAK-endo expression and pFAK-endo overexpression are represented in the left and right panels, respectively. Images were captured at original magnification 200×. (C) Representative CD31 (left panel) and pFAK^Y397 (center panel) immunofluorescent staining in advanced stage, high grade serous ovarian cancer. Dual CD31 and pFAK^Y397 staining (right panel) demonstrates activated FAK in the tumor vasculature. Images were captured at original magnification 200×. (D) Quantitative real-time PCR of endothelial cell FAK expression. FAK gene expression in 10 ovarian cancer isolates was calculated as the mean fold change relative to 7 normal ovarian endothelial specimens (normal = 1) using the 2^−ΔΔC_T method. (E) Kaplan–Meier plot depicting the impact of tumor-associated endothelial cell pFAK^Y397 (pFAK-endo) expression on ovarian cancer patient survival using the log-rank statistic.